FDA RULES // WHAT THEY MEAN
MOTS-c legal status and the one-patient pharmacy rule
Lee's group found this short chain of protein parts while studying how cells use fuel. MOTS-c now has a clinician-reviewed prescription route, but a pharmacy-made drug has no FDA approval.
What the FDA meeting did and didn't mean
FDA advisers discussed MOTS-c legal status at their July 2026 meeting [F3]. They considered a list of raw ingredients, meaning the substances pharmacies may use when mixing a drug for one patient.
An advisory discussion isn't a final FDA ruling. MOTS-c still has no FDA drug approval; research-labelled material remains on sale alongside prescription care that depends on a clinician's decision.
I can explain the broad rule, but I can't give you legal or medical advice. The site doesn't sell or supply MOTS-c.
Here's the part I'd circle for you. A place on a meeting list doesn't mean the FDA has approved a drug.
What MOTS-c is allowed to be used for now
MOTS-c is a tiny 16-amino-acid chain; amino acids are the small parts that make protein. The FDA has not approved it to treat any illness [F1].
No FDA-approved MOTS-c drug form or use exists for people. MOTS-c remains sold for research [4]; a compounded prescription product involves a separate clinical decision.
Federal section 503A covers a pharmacy making a drug for one named patient. For you, that means your doctor must write a prescription just for you.
A raw ingredient—the substance used to make your drug—must be in the main drug book, used in an approved drug, or named on the FDA's allowed list [F1]. MOTS-c's withdrawn nomination does not place it on the FDA's allowed list.
The FDA's safety-risk listing now puts MOTS-c among substances whose nominations were withdrawn. That withdrawal is neither a Category 1 placement nor a finding that the FDA's safety concerns have been resolved.
A compounded MOTS-c prescription does not make the product an FDA-approved drug. Prescribing also does not establish that a bulk ingredient meets every compounding rule [F1].
What being on the July 2026 meeting list meant
The FDA meeting paper named MOTS-c for discussion on July 23-24, 2026. Advisers considered whether it belonged on the raw-ingredient list for drugs made for one patient [F3].
The paper also listed BPC-157, TB-500, and KPV, which are names for other lab compounds [F3]. Those names don't establish permission to compound MOTS-c.
An adviser's recommendation and a final FDA listing are separate steps. The calendar describes a discussion, rather than a final FDA decision [F3].
The meeting calendar cited here does not establish a final 503A listing for MOTS-c. Listing a raw ingredient requires a separate FDA rulemaking step [F1].
The calendar cannot tell you the meeting's result. It records the agenda, rather than a vote or a finished FDA rule.
MOTS-c is listed by the FDA as a substance whose nomination was withdrawn. Withdrawal does not give a pharmacy blanket permission to make a drug; the ingredient and patient rules still apply [F1].
What the 503A and 503B pharmacy rules do
Federal law has two sections for pharmacies that mix drugs [F1]. Section 503A means a pharmacy makes a drug for you alone after your doctor writes your prescription.
Section 503B covers special sites that make larger batches. If your drug came from such a site, the site would register with the FDA and face more checks.
A raw ingredient—the substance used to make your drug—must be in the main drug book, used in an approved drug, or named on the right FDA list [F1]. That rule protects your prescription as well as other people's drugs.
A nomination for FDA review is not a substitute for meeting an ingredient test [F1]. A finished drug must pass its own approval review, which is a separate legal question for you.
MOTS-c has no FDA drug approval, and withdrawing its nomination does not create a final 503A list entry. Prescription access begins with a case review; it does not settle the separate compounding rules [F1].
Both your doctor and pharmacy must follow those rules for your prescription. A meeting notice, a seller's claim, or someone else's prescription can't prove MOTS-c is lawful for you.
What must happen before a pharmacy mixes a drug
A drug mixed just for you starts with you and a licensed doctor. The doctor reviews your health, decides whether the drug fits, and writes your prescription [F2].
A state-licensed 503A pharmacy may then make your one-patient drug. A registered 503B site may make larger batches under more FDA checks [F2].
A video or phone visit can be how you meet the doctor. It doesn't change which raw ingredients are allowed or remove the need for your real doctor-patient link and prescription [F2].
The FDA can bar a raw ingredient from this kind of mixing if it finds a major safety risk [F2]. MOTS-c's entry in the FDA safety-risk listing still carries concerns despite withdrawal of its nomination.
For your own case, these broad rules can't replace advice from your doctor or lawyer [F2]. The rules also don't make any seller or dose lawful for you.